Bayer has submitted Eylea for European approval for use in macular oedema following branch retinal vein occlusion (BRVO). The injectable biologic is competing with Novartis' rival Lucentis in the ...

n = 2 in second-year BRVO n = 3.5 in second-year CRVO BCVA gained >15 letters in 2 years: 39% in BRVO; 21% in CRVO (no differences in primary end points of all measures between 2 agents ...